Anixa Biosciences (NASDAQ:ANIX) Coverage Initiated at Maxim Group

Equities researchers at Maxim Group initiated coverage on shares of Anixa Biosciences (NASDAQ:ANIX) in a note issued to investors on Friday, MarketBeat.com reports. The brokerage set a “buy” rating and a $10.00 price target on the stock. Maxim Group’s price objective would suggest a potential upside of 216.46% from the company’s previous close.

ANIX has been the subject of a number of other reports. D. Boral Capital restated a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a report on Wednesday, January 22nd. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Anixa Biosciences in a research note on Tuesday, February 18th.

Anixa Biosciences Trading Up 0.3 %

NASDAQ ANIX opened at $3.16 on Friday. Anixa Biosciences has a 1-year low of $2.07 and a 1-year high of $4.20. The company has a market capitalization of $101.74 million, a PE ratio of -8.10 and a beta of 0.86. The firm’s fifty day simple moving average is $2.89 and its 200-day simple moving average is $3.01.

Anixa Biosciences (NASDAQ:ANIX) last posted its earnings results on Tuesday, March 11th. The company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). As a group, analysts predict that Anixa Biosciences will post -0.41 EPS for the current year.

Insider Activity at Anixa Biosciences

In other Anixa Biosciences news, Director Lewis H. Titterton, Jr. bought 10,000 shares of the stock in a transaction on Friday, January 17th. The stock was purchased at an average price of $2.57 per share, with a total value of $25,700.00. Following the acquisition, the director now owns 922,334 shares of the company’s stock, valued at approximately $2,370,398.38. The trade was a 1.10 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Amit Kumar purchased 43,000 shares of Anixa Biosciences stock in a transaction dated Wednesday, January 15th. The shares were purchased at an average cost of $2.23 per share, for a total transaction of $95,890.00. Following the completion of the transaction, the chief executive officer now owns 559,925 shares of the company’s stock, valued at approximately $1,248,632.75. This represents a 8.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 75,289 shares of company stock valued at $177,021 over the last quarter. Corporate insiders own 25.30% of the company’s stock.

Hedge Funds Weigh In On Anixa Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC bought a new position in shares of Anixa Biosciences during the fourth quarter worth $26,000. Virtu Financial LLC bought a new stake in Anixa Biosciences in the 3rd quarter valued at $34,000. Renaissance Technologies LLC lifted its position in Anixa Biosciences by 36.5% in the 4th quarter. Renaissance Technologies LLC now owns 14,573 shares of the company’s stock valued at $34,000 after acquiring an additional 3,900 shares in the last quarter. Prosperity Wealth Management Inc. acquired a new stake in Anixa Biosciences in the 4th quarter valued at $54,000. Finally, Jane Street Group LLC acquired a new stake in Anixa Biosciences in the 4th quarter valued at $67,000. 29.13% of the stock is owned by institutional investors.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.